A fixed-dose combination (FDC) medication used primarily for the management of diabetic peripheral neuropathy (DPN). Epalrestat is an aldose reductase inhibitor (ARI) that reduces the accumulation of sorbitol in nerve cells, a key pathological factor in diabetic neuropathy. Methylcobalamin is an active form of Vitamin B12 that supports nerve regeneration, myelin synthesis, and neuronal function. This combination targets both the metabolic pathway causing nerve damage and provides nutritional support for nerve repair, making it a cornerstone therapy for symptomatic DPN in India.
Adult: One tablet of Epalrestat 50mg + Methylcobalamin 500mcg, orally, three times a day (TID), preferably before meals.
Note: Swallow the tablet whole with a glass of water. Take before meals to improve absorption consistency. Do not crush or chew. Therapy is long-term; consistent daily intake is crucial for efficacy.
The combination works via two complementary pathways. Epalrestat inhibits the enzyme aldose reductase in the polyol pathway. In hyperglycemia, excess glucose is shunted into this pathway, leading to accumulation of sorbitol and fructose within nerve cells, causing osmotic stress, depletion of myo-inositol, and reduced Na+/K+ ATPase activity, ultimately resulting in axonal degeneration and impaired nerve conduction velocity. By inhibiting aldose reductase, Epalrestat reduces sorbitol levels. Methylcobalamin acts as a coenzyme for methionine synthase, essential for the synthesis of methionine and S-adenosylmethionine (involved in phospholipid and myelin synthesis), and for L-methylmalonyl-CoA mutase, crucial for fatty acid metabolism in neurons. It promotes nerve regeneration, repairs damaged myelin sheaths, and improves neuronal function.
Pregnancy: Category N (Not classified by US FDA). Indian context: Contraindicated. Animal studies with Epalrestat have shown fetal toxicity. Adequate and well-controlled studies in pregnant women are lacking. Use only if potential benefit justifies potential risk to the fetus.
Driving: Dizziness has been reported. Patients should be cautioned about operating machinery or driving until they are certain the medication does not affect them adversely.
| Chloramphenicol | May decrease the hematopoietic response to Methylcobalamin. | Moderate |
| Proton Pump Inhibitors (Omeprazole, Pantoprazole) | Long-term use may reduce absorption of dietary Vitamin B12; however, effect on pharmacological Methylcobalamin dose is likely minimal. | Low |
| Metformin | Long-term use may reduce serum Vitamin B12 levels. The high-dose Methylcobalamin in this FDC is intended to overcome this. | Low |
| Colchicine | May impair Vitamin B12 absorption. | Moderate |
| Antiepileptics (Phenytoin, Phenobarbital) | May reduce serum Methylcobalamin levels. | Moderate |
| Alcohol (Chronic use) | Can exacerbate neuropathy and may reduce the efficacy of therapy. | High |
Same composition (Epalrestat (50mg) + Methylcobalamin (500mcg)), different brands: